NCT01716806 2024-06-11A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)Seagen Inc.Phase 2 Completed131 enrolled 28 charts